Sienna Biopharmaceuticals, Inc.
SNNAQ
$0.00
$0.000.00%
OTC PK
| 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | 09/30/2018 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -13.28% | 5.98% | 14.87% | 42.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -23.42% | 13.57% | 50.38% | 81.51% |
| Operating Income | -- | 23.42% | -13.57% | -50.38% | -81.51% |
| Income Before Tax | -- | 6.62% | -25.90% | -44.53% | -36.67% |
| Income Tax Expenses | -- | -- | -- | -- | 63.21% |
| Earnings from Continuing Operations | -- | 6.39% | -26.43% | -45.36% | -37.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 6.39% | -26.43% | -45.36% | -37.11% |
| EBIT | -- | 23.42% | -13.57% | -50.38% | -81.51% |
| EBITDA | -- | 23.48% | -13.56% | -50.43% | -81.59% |
| EPS Basic | -- | 23.56% | 62.16% | 73.33% | 81.91% |
| Normalized Basic EPS | -- | 33.19% | 65.76% | 73.65% | 80.01% |
| EPS Diluted | -- | 23.56% | 62.16% | 73.33% | 81.91% |
| Normalized Diluted EPS | -- | 33.19% | 65.76% | 73.65% | 80.01% |
| Average Basic Shares Outstanding | -- | 27.77% | 51.16% | 111.43% | 300.40% |
| Average Diluted Shares Outstanding | -- | 27.77% | 51.16% | 111.43% | 300.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |